Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Literature DB >> 26040619

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

Nicole G Chau¹, Jochen H Lorch².

Abstract

Keywords: Drug development; Exceptional responders; Personalized medicine; Precision medicine

Mesh：

Substances：
Biomarkers, Tumor

Year: 2015 PMID： 26040619 PMCID： PMC4492235 DOI： 10.1634/theoncologist.2014-0476

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

8 in total

1. Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors: Alice T Shaw; Jeffrey A Engelman
Journal: N Engl J Med Date: 2014-06-26 Impact factor: 91.245

2. Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Authors: Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Ali Amin-Mansour; Amaro Taylor-Weiner; Mara Rosenberg; Nathanael Gray; Justine A Barletta; Yanan Guo; Scott J Swanson; Daniel T Ruan; Glenn J Hanna; Robert I Haddad; Gad Getz; David J Kwiatkowski; Scott L Carter; David M Sabatini; Pasi A Jänne; Levi A Garraway; Jochen H Lorch
Journal: N Engl J Med Date: 2014-10-09 Impact factor: 91.245

Review 3. Clinical analysis and interpretation of cancer genome data.

Authors: Eliezer M Van Allen; Nikhil Wagle; Mia A Levy
Journal: J Clin Oncol Date: 2013-04-15 Impact factor: 44.544

4. Genome sequencing identifies a basis for everolimus sensitivity.

Authors: Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal: Science Date: 2012-08-23 Impact factor: 47.728

5. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Authors: Nikhil Wagle; Brian C Grabiner; Eliezer M Van Allen; Eran Hodis; Susanna Jacobus; Jeffrey G Supko; Michelle Stewart; Toni K Choueiri; Leena Gandhi; James M Cleary; Aymen A Elfiky; Mary Ellen Taplin; Edward C Stack; Sabina Signoretti; Massimo Loda; Geoffrey I Shapiro; David M Sabatini; Eric S Lander; Stacey B Gabriel; Philip W Kantoff; Levi A Garraway; Jonathan E Rosenberg
Journal: Cancer Discov Date: 2014-03-13 Impact factor: 39.397

6. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Authors: Jianjun Zhang; Junya Fujimoto; Jianhua Zhang; David C Wedge; Xingzhi Song; Jiexin Zhang; Sahil Seth; Chi-Wan Chow; Yu Cao; Curtis Gumbs; Kathryn A Gold; Neda Kalhor; Latasha Little; Harshad Mahadeshwar; Cesar Moran; Alexei Protopopov; Huandong Sun; Jiabin Tang; Xifeng Wu; Yuanqing Ye; William N William; J Jack Lee; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; P Andrew Futreal
Journal: Science Date: 2014-10-10 Impact factor: 47.728

7. Bioinformatics challenges for personalized medicine.

Authors: Guy Haskin Fernald; Emidio Capriotti; Roxana Daneshjou; Konrad J Karczewski; Russ B Altman
Journal: Bioinformatics Date: 2011-05-19 Impact factor: 6.937

8. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

Authors: Elza C de Bruin; Nicholas McGranahan; Richard Mitter; Max Salm; David C Wedge; Lucy Yates; Mariam Jamal-Hanjani; Seema Shafi; Nirupa Murugaesu; Andrew J Rowan; Eva Grönroos; Madiha A Muhammad; Stuart Horswell; Marco Gerlinger; Ignacio Varela; David Jones; John Marshall; Thierry Voet; Peter Van Loo; Doris M Rassl; Robert C Rintoul; Sam M Janes; Siow-Ming Lee; Martin Forster; Tanya Ahmad; David Lawrence; Mary Falzon; Arrigo Capitanio; Timothy T Harkins; Clarence C Lee; Warren Tom; Enock Teefe; Shann-Ching Chen; Sharmin Begum; Adam Rabinowitz; Benjamin Phillimore; Bradley Spencer-Dene; Gordon Stamp; Zoltan Szallasi; Nik Matthews; Aengus Stewart; Peter Campbell; Charles Swanton
Journal: Science Date: 2014-10-10 Impact factor: 47.728

8 in total

1. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.

Authors: J Alexander Bodkin; Michael J Coleman; Laura J Godfrey; Claudia M B Carvalho; Charity J Morgan; Raymond F Suckow; Thea Anderson; Dost Öngür; Marc J Kaufman; Kathryn E Lewandowski; Arthur J Siegel; Elliot Waldstreicher; Christopher M Grochowski; Daniel C Javitt; Dan Rujescu; Scott Hebbring; Richard Weinshilboum; Stephanie Burgos Rodriguez; Colette Kirchhoff; Timothy Visscher; Alexander Vuckovic; Allison Fialkowski; Shane McCarthy; Dheeraj Malhotra; Jonathan Sebat; Donald C Goff; James I Hudson; James R Lupski; Joseph T Coyle; Uwe Rudolph; Deborah L Levy
Journal: Biol Psychiatry Date: 2019-05-09 Impact factor: 13.382

2. Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.

Authors: Gaye Lightbody; Valeriia Haberland; Fiona Browne; Laura Taggart; Huiru Zheng; Eileen Parkes; Jaine K Blayney
Journal: Brief Bioinform Date: 2019-09-27 Impact factor: 11.622

Review 3. Defining actionable mutations for oncology therapeutic development.

Authors: T Hedley Carr; Robert McEwen; Brian Dougherty; Justin H Johnson; Jonathan R Dry; Zhongwu Lai; Zara Ghazoui; Naomi M Laing; Darren R Hodgson; Francisco Cruzalegui; Simon J Hollingsworth; J Carl Barrett
Journal: Nat Rev Cancer Date: 2016-04-26 Impact factor: 60.716

4. OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine.

Authors: John Orechia; Ameet Pathak; Yunling Shi; Aniket Nawani; Andrey Belozerov; Caitlin Fontes; Camille Lakhiani; Chetan Jawale; Chetansharan Patel; Daniel Quinn; Dmitry Botvinnik; Eddie Mei; Elizabeth Cotter; James Byleckie; Mollie Ullman-Cullere; Padam Chhetri; Poornima Chalasani; Purushotham Karnam; Ronald Beaudoin; Sandeep Sahu; Yelena Belozerova; Jomol P Mathew
Journal: Appl Transl Genom Date: 2015-09-14

Review 8. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.

Authors: Ping-Pin Zheng; Jin Li; Johan M Kros
Journal: Med Res Rev Date: 2017-09-01 Impact factor: 12.944

8 in total

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back.

1. Ceritinib in ALK-rearranged non-small-cell lung cancer.

2. Response and acquired resistance to everolimus in anaplastic thyroid cancer.

Review 3. Clinical analysis and interpretation of cancer genome data.

4. Genome sequencing identifies a basis for everolimus sensitivity.

5. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

6. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

7. Bioinformatics challenges for personalized medicine.

8. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.

1. Targeted Treatment of Individuals With Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene.

2. Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application.

Review 3. Defining actionable mutations for oncology therapeutic development.

4. OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine.

Review 5. Implementation of "clinical sequencing" in cancer genome medicine in Japan.

Review 6. Learning From the Exceptions: HIV Remission in Post-treatment Controllers.

Review 7. Biomarkers for immunotherapy for treatment of glioblastoma.

Review 8. Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.